Meyer Handelman Company’s AbbVie ABBV Stock Holding History

Meyer Handelman Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.8M	Buy	178,325 +1,830	+1%	+$406K	1.21%	26
2025 Q4	$40.3M	Buy	176,495 +6,531	+4%	+$1.49M	1.26%	23
2025 Q3	$39.4M	Buy	169,964 +5,098	+3%	+$1.04M	1.24%	24
2025 Q2	$30.6M	Buy	164,866 +2,622	+2%	+$487K	1.01%	32
2025 Q1	$34M	Buy	162,244 +7,383	+5%	+$1.44M	1.18%	27
2024 Q4	$27.5M	Buy	154,861 +1,621	+1%	+$298K	0.95%	34
2024 Q3	$30.3M	Buy	153,240 +5,162	+3%	+$963K	1.02%	34
2024 Q2	$25.4M	Buy	148,078 +8,395	+6%	+$1.39M	0.89%	35
2024 Q1	$25.4M	Buy	139,683 +1,823	+1%	+$314K	0.89%	37
2023 Q4	$21.4M	Buy	137,860 +1,625	+1%	+$237K	0.83%	37
2023 Q3	$20.3M	Buy	136,235 +8,430	+7%	+$1.24M	0.82%	37
2023 Q2	$17.2M	Sell	127,805 -560	-0.4%	-$82.1K	0.7%	46
2023 Q1	$20.5M	Sell	128,365 -380	-0.3%	-$58.1K	0.86%	40
2022 Q4	$20.8M	Sell	128,745 -200	-0.2%	-$30.7K	0.87%	38
2022 Q3	$17.3M	Sell	128,945 -1,510	-1%	-$217K	0.8%	42
2022 Q2	$20M	Buy	130,455 +188	+0.1%	+$28.7K	0.86%	39
2022 Q1	$21.1M	Sell	130,267 -800	-0.6%	-$116K	0.81%	43
2021 Q4	$17.7M	Buy	131,067 +4,657	+4%	+$550K	0.66%	52
2021 Q3	$13.6M	Buy	126,410 +100	+0.1%	+$11.4K	0.56%	58
2021 Q2	$14.2M	Buy	126,310 +2,800	+2%	+$315K	0.56%	57
2021 Q1	$13.4M	Buy	123,510 +2,550	+2%	+$273K	0.55%	58
2020 Q4	$13M	Buy	120,960 +7,950	+7%	+$764K	0.59%	54
2020 Q3	$9.9M	Sell	113,010 -3,100	-3%	-$292K	0.5%	60
2020 Q2	$11.4M	Buy	116,110 +3,110	+3%	+$274K	0.61%	51
2020 Q1	$8.61M	Buy	113,000 +999	+0.9%	+$85.1K	0.53%	54
2019 Q4	$9.92M	Buy	112,001 +4,000	+4%	+$332K	0.48%	63
2019 Q3	$8.18M	Buy	108,001 +3,320	+3%	+$228K	0.41%	68
2019 Q2	$7.61M	Buy	104,681 +5,334	+5%	+$419K	0.39%	69
2019 Q1	$7.76M	Hold	99,347	–	–	0.4%	68
2018 Q4	$9.16M	Sell	99,347 -5,000	-5%	-$440K	0.52%	58
2018 Q3	$9.87M	Sell	104,347 -400	-0.4%	-$37.9K	0.48%	61
2018 Q2	$9.71M	Buy	104,747 +5,866	+6%	+$573K	0.5%	59
2018 Q1	$9.36M	Sell	98,881 -3,100	-3%	-$341K	0.48%	61
2017 Q4	$9.86M	Hold	101,981	–	–	0.47%	59
2017 Q3	$9.06M	Buy	101,981 +6,765	+7%	+$515K	0.41%	68
2017 Q2	$6.9M	Hold	95,216	–	–	0.29%	88
2017 Q1	$6.2M	Buy	95,216 +5,766	+6%	+$363K	0.26%	89
2016 Q4	$5.6M	Buy	89,450 +500	+0.6%	+$30.5K	0.25%	92
2016 Q3	$5.61M	Buy	88,950 +400	+0.5%	+$25.9K	0.25%	93
2016 Q2	$5.48M	Buy	88,550 +2,500	+3%	+$152K	0.25%	89
2016 Q1	$4.92M	Buy	86,050 +250	+0.3%	+$13.9K	0.23%	96
2015 Q4	$5.08M	Buy	85,800 +1,600	+2%	+$92.2K	0.24%	92
2015 Q3	$4.58M	Buy	84,200 +1,700	+2%	+$111K	0.23%	95
2015 Q2	$5.54M	Hold	82,500	–	–	0.25%	93
2015 Q1	$4.83M	Hold	82,500	–	–	0.22%	96
2014 Q4	$5.4M	Hold	82,500	–	–	0.24%	95
2014 Q3	$4.76M	Sell	82,500 -200	-0.2%	-$11.1K	0.22%	96
2014 Q2	$4.67M	Buy	82,700 +400	+0.5%	+$21K	0.22%	97
2014 Q1	$4.23M	Sell	82,300 -500	-0.6%	-$25.3K	0.2%	97
2013 Q4	$4.37M	Hold	82,800	–	–	0.21%	95
2013 Q3	$3.7M	Buy	82,800 +3,950	+5%	+$175K	0.2%	95
2013 Q2	$3.26M	Buy	+78,850	New	+$3.45M	0.18%	98

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meyer Handelman Company's ABBV Position: Q1 2026 in Review

Meyer Handelman Company increased its AbbVie (ABBV) stake by 1% in Q1 2026, buying an estimated $406K and bringing the position to 178,325 shares worth $38.8M. The position accounts for 1.21% of the portfolio, ranked #26.

Meyer Handelman Company first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.3M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Meyer Handelman Company held 178,325 shares of AbbVie worth $38.8M as of Q1 2026.
Meyer Handelman Company bought 1,830 AbbVie shares in Q1 2026, an estimated $406K.
AbbVie made up 1.21% of Meyer Handelman Company's portfolio in Q1 2026, its #26 holding.
Meyer Handelman Company first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Meyer Handelman Company's AbbVie position peaked at $40.3M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Meyer Handelman Company's 13F filing for Q1 2026, filed 20 Apr 2026.